/

Società

AA

Non verificato

AAVantgarde

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaLegge/Diritto/FiscoMedicina Salute Benessere

18 comunicati stampa

Guarda tutti i comunicati

04/10/2026

Biotecnologia

Medicina Salute Benessere

Annunci Economici

AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026

Fonte

Emittente

1.00

0

16/09/2026

Biotecnologia

Medicina Salute Benessere

AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026

Fonte

Emittente

1.00

0

01/09/2026

Biotecnologia

AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer

Fonte

Emittente

1.00

0

23/07/2026

Biotecnologia

AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy

Fonte

Emittente

1.00

0

23/04/2026

Biotecnologia

AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study

Fonte

Emittente

1.00

0

21/04/2026

Biotecnologia

Annunci Economici

AAVantgarde announces completion of recruitment in STELLA natural history study

Fonte

Emittente

1.00

0

01/04/2026

Biotecnologia

AAVantgarde appoints Philip Lao as Senior Vice President of Business Development

Fonte

Emittente

1.00

0

15/01/2026

Biotecnologia

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa

Fonte

Emittente

1.00

0

08/01/2026

Biotecnologia

AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference

Fonte

Emittente

1.00

0

03/11/2025

Biotecnologia

Finanza

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0